Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in relapsed/refractory precursor B-cell ALL (China, Phase III)
CTR20170176Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2017
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Boehringer Ingelheim. Started Aug 2017; status: completed.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on CTR20170176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170176.